Platform
Company
Coagulation
Review status
Currently under review
Pending specialist review and validation.
This test measures the functional activity of factor XI, a clotting protein made in the liver that helps your body form stable blood clots. Factor XI works as part of the intrinsic pathway of coagulation, helping generate thrombin and strengthen the clot.
The designation 1:20 refers to the dilution used in the laboratory assay. Using a defined dilution helps the lab assess how well factor XI works in your plasma and reduces interference from other components. The result reflects activity, not the amount of protein, and is used alongside your history, exam, and other lab tests.
Your care team may order this test if you have easy bleeding after dental work or surgery, a personal or family history suggesting a bleeding tendency, or an unexplained prolongation on screening clotting tests. It can help distinguish inherited factor XI deficiency from acquired causes related to other medical conditions or medications.
Understanding factor XI activity can guide decisions before procedures and in specific clinical situations. Low activity may increase bleeding risk in settings with tissue injury, while very high levels have been linked to a higher likelihood of forming clots. Results can influence choices such as the use of antifibrinolytic medicines, plasma products, or adjustments to anticoagulant therapy.
If your result is below the laboratory’s reference interval, it may indicate an inherited deficiency, an acquired decrease due to liver disease or other illnesses, or interference from medications that affect clotting tests. Your provider may review your bleeding history, repeat the test to confirm, or order related studies such as a mixing study, screening for inhibitors, and measurement of other clotting factors.
If your result is above the reference interval, interpretation depends on your situation and other tests. Some conditions and hormones can shift coagulation balance, and elevated activity has been associated with an increased tendency to clot. Regardless of direction, discuss your medications, recent procedures, and any bleeding or clotting symptoms with your clinician. Further evaluation is tailored to your risks, upcoming procedures, and overall health.
Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.
Underfilled or overfilled citrate tubes, clotted samples, or delays in processing can falsely alter activity results. A proper citrate-to-blood ratio and prompt centrifugation are important for accurate testing.
Blood drawn through heparinized lines, or recent heparin exposure, can depress activity measurements. Drawing from a peripheral stick and discarding an initial aliquot can reduce this interference.
Medications such as apixaban, rivaroxaban, dabigatran, and warfarin can affect clot-based assays and make factor activity appear lower or inconsistent. Your clinician may time blood draws or use alternate methods if needed.
Antiphospholipid antibodies and specific factor XI inhibitors can prolong clotting assays and mimic deficiency. Mixing studies and inhibitor screens help distinguish these causes from true low factor levels.
Because factor XI is produced in the liver, liver dysfunction can lower levels. Severe illness, disseminated intravascular coagulation, or significant blood loss can also reduce activity.
Newborns naturally have lower levels of several contact factors, and pregnancy can shift coagulation balance, so results are interpreted in context. Inherited factor XI deficiency is more frequent in some populations; family history helps guide testing.
References